Novartis has joined forces with Amazon, drawing on the online retail giant’s technological wizardry to reduce bottlenecks and improve the efficiency of its manufacturing and distribution.
The deal with Amazon Web Services (AWS) is aimed at using the tech company’s cloud-based systems to collect inventory, quality, and production data across its network into central hubs, dubbed Insight Centres, that Novartis says will help it to track production in real time.
The increase in efficacy is essential in light of a shift in the industry towards the production of personalised therapies – such as Novartis’ CAR-T Kymriah (tisagenlecleucel) for blood cancers – which are more complex to make than conventional drugs.
For Novartis, partnering with AWS buys into the many years Amazon has spent developing supply chain and automation systems that enable millions of products to be delivered to hundreds of millions of individuals.
Financial terms of the deal – which comes four years after the two companies first started working together – aren’t being disclosed. The deal also follows Novartis’ wide-ranging partnership with Microsoft to develop artificial intelligence tools for use in its R&D operations.
Novartis’ global head of strategy and operations Amit Nastik said pharma manufacturing as a whole is not as advanced as manufacturing in other industries, and because it is highly regulated “there is a natural hesitancy to try technology that is not fully proven.”
“The Insight Centres will allow us to look at our whole value chain from the start to the end, from how we source our material, how we do our demand forecasting, how we operate at the shop floor, to how we supply our customers and patients,” he added.
For instance, Novartis plans to use AWS Internet of Things (IoT) services to develop better visual inspections of manufacturing sites by generating images that can be analysed using computer vision algorithms.
That will improve its ability to monitor for risks to manufacturing production, such as unplanned downtime or delayed orders.
Meanwhile, for Amazon the deal marks another element of its push into the healthcare sector with deals such as its recent purchase of online symptom checking and triage tool specialist Health Navigator, and online pharmacy player PillPack.
By Phil Taylor
Source: PharmaPhorum
Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.
Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.
Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.
